# Cognition Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cognition Therapeutics, Inc). ## Overview Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on small-molecule therapies for age-related degenerative diseases of the central nervous system and retina. Its lead program, zervimesine (CT1812), is being developed to target the sigma-2 receptor complex and reduce the toxicity of amyloid beta oligomers, with the company positioning the drug for diseases such as dementia with Lewy bodies, Alzheimer’s disease, and geographic atrophy. The business is still in development mode, so it does not yet generate product revenue and depends on external financing, grants, and potential partnerships to fund research and clinical trials. Its value proposition is tied to whether zervimesine can show disease-modifying benefit in late-stage studies and ultimately secure regulatory approval. ## Products & services • Zervimesine (CT1812) clinical development • DLB expanded access program (EAP) • Alzheimer’s disease clinical programs • Geographic atrophy / dry AMD research • Preclinical discovery of sigma-2 receptor therapeutics • Drug manufacturing and supply via third parties - **Lead clinical candidate** (85%) — Development of zervimesine (CT1812) for neurodegenerative and retinal diseases. - **Expanded access and clinical support** (5%) — Patient access programs and trial-related support for eligible DLB participants. - **Preclinical pipeline** (10%) — Discovery-stage work on additional sigma-2 receptor-based therapeutics. - Zervimesine (CT1812) clinical development - DLB expanded access program (EAP) - Alzheimer’s disease clinical programs - Geographic atrophy / dry AMD research - Preclinical discovery of sigma-2 receptor therapeutics - Drug manufacturing and supply via third parties ## Customers Cognition does not currently sell approved products to commercial end customers; its near-term “customers” are primarily clinical trial participants, investigators, and trial sites that enroll patients into its studies. The company’s lead program is aimed at patients with dementia with Lewy bodies, Alzheimer’s disease, and related age-related degenerative disorders, where unmet medical need is high and current treatment options are limited. In the expanded access program, eligible U.S. patients with mild-to-moderate DLB who completed the Phase 2 study or meet program criteria can receive zervimesine outside a standard trial setting. Longer term, if approved, the company would need to serve neurologists, memory clinics, retina specialists, and potentially commercialization partners that would help bring the therapy to market. - **Clinical trial participants** (primary) — Patients with DLB, Alzheimer’s disease, or related disorders who enroll in studies to receive zervimesine and generate efficacy/safety data. - **Clinical research sites and investigators** (primary) — Hospitals and specialty centers that recruit, dose, monitor, and assess patients in Cognition-sponsored trials. - **Expanded access patients** (secondary) — Eligible DLB patients in the U.S. who receive daily oral zervimesine through the philanthropic-funded access program. - **Future prescribers and health systems** (emerging) — Neurologists, memory clinics, and specialty providers that would use the drug if it gains approval. - **Commercial partners** (emerging) — Potential third parties for ex-U.S. development, licensing, or commercialization if the company seeks to reduce go-to-market burden. - DLB patients enrolled in Phase 2 studies and expanded access programs - Alzheimer’s disease trial participants recruited for cognitive endpoints - Clinical investigators and U.S. trial sites running the studies - Future prescribing physicians in neurology and memory care - Potential commercialization partners outside the United States ## Geography Cognition is headquartered in the United States and its current operating footprint is centered on U.S.-based clinical development. The company disclosed eight U.S. sites for the expanded access program, all of which were active in the SHIMMER study, underscoring that its near-term execution is concentrated in domestic trial infrastructure. It also states that it may seek collaborations to commercialize zervimesine outside the United States, which suggests future geographic expansion could depend on partnerships rather than owned international operations. Because it does not own manufacturing facilities, its geographic exposure also includes third-party manufacturing and supply chains that may be located outside its headquarters market. - Headquartered and primarily operating in the United States - Eight U.S. sites selected for the DLB expanded access program - Clinical development is currently concentrated in U.S. trial infrastructure - Potential future commercialization outside the United States may rely on partners - Third-party manufacturing and supply chain geography can affect trial and launch readiness ## Strategy Cognition’s core strategy is to advance zervimesine through clinical development and use the data package to support regulatory discussions with the FDA. The company is focusing on diseases with limited treatment options, which increases the potential clinical and commercial value if the drug demonstrates meaningful benefit. It is also preserving capital by outsourcing manufacturing, packaging, labeling, storage, and distribution rather than building internal facilities. Because it has no product sales yet, the company must continue raising capital, pursuing grants, and potentially forming partnerships to fund the next stages of development and eventual commercialization. - **Complete the Phase 3 development plan for zervimesine** (short-term) — Regulatory approval depends on translating Phase 2 signals into a larger confirmatory program acceptable to the FDA. - **Maintain clinical momentum in DLB and related CNS indications** (short-term) — The company needs continued efficacy and safety evidence to support differentiation and future partnering. - **Preserve capital through an outsourced operating model** (medium-term) — As a clinical-stage company with no product revenue, cash efficiency is essential to fund trials and regulatory work. - **Secure non-dilutive and dilutive funding** (short-term) — The company will need substantial additional capital before any commercial revenue is available. - Advance zervimesine through late-stage clinical development - Use sigma-2 receptor biology as a differentiated mechanism - Target diseases with high unmet need such as DLB and Alzheimer’s disease - Outsource manufacturing and supply chain functions to preserve cash - Seek additional funding through equity, debt, grants, or partnerships - Consider ex-U.S. commercialization collaborations to reduce launch burden ## Risks Cognition faces the classic risks of a clinical-stage biotech: its lead asset may fail to show sufficient efficacy, safety, or durability in larger trials, which would materially reduce the value of the pipeline. The company is also highly dependent on external capital because it has no product sales and expects continued losses until approval, so financing conditions directly affect its ability to keep developing zervimesine. Regulatory risk is meaningful because FDA review timing, staffing, and policy changes can delay or complicate development and approval. In addition, the company relies on third-party CROs and CMOs, so operational disruptions, manufacturing delays, or supply issues could affect trial execution and future launch readiness. - **Clinical development failure for zervimesine** [critical] — The company’s value depends heavily on one lead asset, and late-stage trials may not confirm efficacy or safety seen in Phase 2. - **Dependence on external financing** [high] — The company expects significant losses and needs substantial additional funding before any product revenue is possible. - **FDA and government funding disruption** [high] — Delays or staffing constraints at the FDA can slow review, approval, or guidance on the Phase 3 program. - **Third-party manufacturing and CRO dependence** [medium] — The company does not own manufacturing facilities and relies on vendors for trial supply and future commercial production. - **Safety/tolerability concerns** [medium] — Observed treatment-emergent liver function test elevations could become more important as exposure expands. - Clinical failure risk if zervimesine does not replicate Phase 2 signals in larger studies - Financing risk because the company has no product revenue and needs ongoing capital - Regulatory risk from FDA timing, staffing, and policy changes - Manufacturing and supply-chain risk due to reliance on third parties - Execution risk if trial enrollment, endpoints, or site operations underperform - Broader biotech risk from safety findings, including liver function test elevations ## Accounting As a clinical-stage biotech, Cognition’s reported results are driven mainly by research and development expense, stock-based compensation, and other operating costs rather than product revenue. Clinical trial spending can fluctuate sharply quarter to quarter depending on enrollment, CRO activity, and manufacturing of clinical supply, which makes period comparisons volatile. The company also relies on estimates for accrued trial costs, vendor services, and grant-related income, so timing differences between services received and invoices paid can affect reported expenses. Lease accounting is modest but still relevant because the company leases office space, while equity financing and warrant issuance can create dilution and require careful classification and valuation. - **Research and development accruals** — Affects operating loss and comparability across periods - **Grant income recognition** — Affects other income and reported burn rate - **Stock-based compensation** — Affects G&A and total operating expenses - **Lease accounting** — Affects balance sheet leverage and occupancy expense - **Warrants and equity financing** — Affects share count, equity, and per-share valuation - R&D expense timing depends on CRO and CMO activity, causing quarterly volatility - Clinical supply manufacturing costs can shift with replenishment cycles - Accrual estimates for trial services affect expense recognition - Stock-based compensation influences G&A and total operating loss - Grant income recognition can offset operating expenses when funding is received - Lease accounting is limited but affects occupancy-related expense recognition - Warrant and equity issuance accounting can affect dilution and equity presentation --- *Last updated: 2026-08-11T04:46:26.665334+00:00*